mitoxantrone has been researched along with Innate Inflammatory Response in 13 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mitoxantrone is a member of the anthracendione family developed to treat malignancies and increasingly used to treat multiple sclerosis (MS)." | 8.82 | Rationale for the use of mitoxantrone in multiple sclerosis. ( Edan, G; Le Page, E; Morrissey, S, 2004) |
| "Mitoxantrone (MITX) and cyclophosphamide (CPM) are potent immunosuppressive agents with efficacy in the treatment of multiple sclerosis (MS)." | 8.82 | The argument against the use of cyclophosphamide and mitoxantrone in the treatment of multiple sclerosis. ( Jeffery, DR, 2004) |
| "Mitoxantrone is a synthetic anthracenedione recently approved by the FDA for the treatment of worsening relapsing-remitting (RR), secondary progressive (SP), and progressive relapsing (PR) multiple sclerosis (MS)." | 8.82 | Review of mitoxantrone in the treatment of multiple sclerosis. ( Herndon, R; Jeffery, DR, 2004) |
| "Mitoxantrone has been approved by the FDA for the treatment of multiple sclerosis (MS)." | 7.78 | Mitoxantrone repression of astrocyte activation: relevance to multiple sclerosis. ( Burns, SA; Chavis, JA; Drew, PD; Hensley, LL; Lee Archer, R; Tull, CA, 2012) |
| "Mitoxantrone is a member of the anthracendione family developed to treat malignancies and increasingly used to treat multiple sclerosis (MS)." | 4.82 | Rationale for the use of mitoxantrone in multiple sclerosis. ( Edan, G; Le Page, E; Morrissey, S, 2004) |
| "Mitoxantrone (MITX) and cyclophosphamide (CPM) are potent immunosuppressive agents with efficacy in the treatment of multiple sclerosis (MS)." | 4.82 | The argument against the use of cyclophosphamide and mitoxantrone in the treatment of multiple sclerosis. ( Jeffery, DR, 2004) |
| "Mitoxantrone is a synthetic anthracenedione recently approved by the FDA for the treatment of worsening relapsing-remitting (RR), secondary progressive (SP), and progressive relapsing (PR) multiple sclerosis (MS)." | 4.82 | Review of mitoxantrone in the treatment of multiple sclerosis. ( Herndon, R; Jeffery, DR, 2004) |
| "Mitoxantrone has been approved by the FDA for the treatment of multiple sclerosis (MS)." | 3.78 | Mitoxantrone repression of astrocyte activation: relevance to multiple sclerosis. ( Burns, SA; Chavis, JA; Drew, PD; Hensley, LL; Lee Archer, R; Tull, CA, 2012) |
| "In a 59 year-old woman, polychemotherapy with cyclophosphamide and mitoxantrone was started because of liver and bone marrow metastases following operative treatment of breast cancer with subsequent X-ray treatment in 1982." | 3.67 | [Localized neutrophilic eccrine hydradenitis in mitoxantrone therapy: a typical side-effect of cytostatic drugs]. ( Bieber, T; Burg, G; Langecker, P, 1988) |
| "As compared with metastatic breast cancer (MBC), high risk breast cancer showed a 2." | 1.31 | Infectious complications in breast cancer patients undergoing peripheral blood stem cell transplantation: a single center retrospective analysis towards outpatient strategy. ( Barbaro, P; Console, G; Iacopino, P; Irrera, G; Martino, M; Messina, G; Morabito, F; Oliva, E; Palazzo, S; Pucci, G, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 9 (69.23) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Saunders, MJ | 1 |
| Edwards, BS | 1 |
| Zhu, J | 1 |
| Sklar, LA | 1 |
| Graves, SW | 1 |
| Clemente, M | 1 |
| De Andrés, PJ | 1 |
| Peña, L | 1 |
| Pérez-Alenza, MD | 1 |
| Burns, SA | 1 |
| Lee Archer, R | 1 |
| Chavis, JA | 1 |
| Tull, CA | 1 |
| Hensley, LL | 1 |
| Drew, PD | 1 |
| Kieseier, BC | 1 |
| Hartung, HP | 1 |
| Edan, G | 1 |
| Morrissey, S | 1 |
| Le Page, E | 1 |
| Jeffery, DR | 3 |
| Herndon, R | 1 |
| Csépány, T | 1 |
| Bereczki, D | 1 |
| Awan, F | 1 |
| Hamadani, M | 1 |
| Devine, S | 1 |
| Morabito, F | 1 |
| Irrera, G | 1 |
| Oliva, E | 1 |
| Console, G | 1 |
| Martino, M | 1 |
| Pucci, G | 1 |
| Messina, G | 1 |
| Barbaro, P | 1 |
| Palazzo, S | 1 |
| Iacopino, P | 1 |
| Hurt, MA | 1 |
| Halvorson, RD | 1 |
| Petr, FC | 1 |
| Cooper, JT | 1 |
| Friedman, DJ | 1 |
| Burg, G | 1 |
| Bieber, T | 1 |
| Langecker, P | 1 |
7 reviews available for mitoxantrone and Innate Inflammatory Response
| Article | Year |
|---|---|
Multiple paradigm shifts in multiple sclerosis.
Topics: Adjuvants, Immunologic; Clinical Trials as Topic; Humans; Inflammation; Interferon-beta; Mitoxantron | 2003 |
Rationale for the use of mitoxantrone in multiple sclerosis.
Topics: Cytokines; Drug Administration Schedule; Drug Therapy, Combination; Humans; Immunosuppressive Agents | 2004 |
The argument against the use of cyclophosphamide and mitoxantrone in the treatment of multiple sclerosis.
Topics: Cyclophosphamide; Disease Progression; Humans; Immunosuppressive Agents; Immunotherapy; Inflammation | 2004 |
Review of mitoxantrone in the treatment of multiple sclerosis.
Topics: Animals; Clinical Trials as Topic; Encephalomyelitis, Autoimmune, Experimental; Humans; Immunosuppre | 2004 |
Use of combination therapy with immunomodulators and immunosuppressants in treating multiple sclerosis.
Topics: Azathioprine; Drug Antagonism; Drug Resistance; Drug Therapy, Combination; Humans; Immunologic Facto | 2004 |
[Immunomodulatory therapy in multiple sclerosis].
Topics: Adjuvants, Immunologic; Cognition; Drug Administration Schedule; Glatiramer Acetate; Humans; Immunos | 2004 |
Eccrine squamous syringometaplasia. A cutaneous sweat gland reaction in the histologic spectrum of 'chemotherapy-associated eccrine hidradenitis' and 'neutrophilic eccrine hidradenitis'.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Atrophy; Cytarabine; Eccrine Glands; Humans; | 1990 |
6 other studies available for mitoxantrone and Innate Inflammatory Response
| Article | Year |
|---|---|
Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
Topics: Animals; Biotinylation; Flow Cytometry; Fluorescence Resonance Energy Transfer; Green Fluorescent Pr | 2010 |
Survival time of dogs with inflammatory mammary cancer treated with palliative therapy alone or palliative therapy plus chemotherapy.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antineoplastic Agents; Breast Neoplasms; D | 2009 |
Mitoxantrone repression of astrocyte activation: relevance to multiple sclerosis.
Topics: Animals; Anti-Inflammatory Agents; Astrocytes; Cell Survival; Cells, Cultured; Electrophoretic Mobil | 2012 |
Paraneoplastic Sweet's syndrome and the pathergy phenomenon.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Diagnosis, Differential; Drug Eruptions; | 2007 |
Infectious complications in breast cancer patients undergoing peripheral blood stem cell transplantation: a single center retrospective analysis towards outpatient strategy.
Topics: Adult; Aged; Ambulatory Care; Anti-Bacterial Agents; Antineoplastic Agents, Alkylating; Antineoplast | 2001 |
[Localized neutrophilic eccrine hydradenitis in mitoxantrone therapy: a typical side-effect of cytostatic drugs].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Eccrine | 1988 |